Karolinska institutet
Stockholm, Solna, 17177, Sweden
NCT Number: NCT05218213
Every-day life means being part of a complex environment and performing complex tasks that usually involve a combination of motor and cognitive skills. However, the process of aging or the sequelae of neurological diseases such as Parkinson's disease (PD) compromises motor-cognitive interaction necessary for an independent lifestyle. While motor-cognitive performance has been identified as an important goal for sustained health across different clinical populations, little is known about underlying brain function leading to these difficulties and how to best target these motor-cognitive difficulties in the context of rehabilitation and exercise interventions.
The challenge of improving treatments of motor-cognitive difficulties (such as dual-tasking and navigation) is daunting, and an important step is arriving at a method that accurately portrays these impairments in an ecological valid state. The investigators aim therefore to explore brain function during complex walking in healthy and PD by investigating the effects of age and neurological disease on motor-cognitive performance and its neural correlates during three conditions of complex walking (dual-task walking, navigation and a combination of both) using non-invasive measures of brain activity (functional near infrared spectrometry, fNIRS) and advanced gait analysis in real time in young, older healthy adults and people with PD.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Stockholm, Solna, 17177, Sweden
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Healthy young:
Inclusion criteria
-18 to 50 years
Exclusion criteria
Healthy elderly:
Inclusion criteria
Exclusion criteria
Parkinson cohort:
Inclusion criteria
Exclusion criteria
Assessment of brain activity with fNIRS and behavioural assessments (motor, motor-cognitive and cognitive) during three complex walking conditions.
Time frame: During the test session during all three conditions
The measurement of changes in concentration of HbO and HHb in the prefrontal cortex will be assessed using a NIRSPORT 2 (NIRx Medizintechnik, Berlin, Germany) device
Time frame: During the test session during all three conditions
Gait variables such as stride time and/or velocity will be analyzed with the APDM mobility system.
Time frame: During the test session during dual task conditions
Cognitive performance of the dual task will be assessed as errors in the response to the Auditory stroop task.
Time frame: During the test session, takes about 50 minutes
The cognitive test battery comprised the following tests: The Color-Word Interference Test (CWIT), Verbal Fluency, Trail Making Test (TMT) and Ray Auditory Verbal Learning Test (RAVLT). Cognitive function will be assessed as a composite measure of these test together.
Time frame: During the test session, takes about 12 minutes
Verbal function, initiation & task-set switching with the Verbal Fluency test from D-KEFS (Delis-Kaplan Executive Function System)
Time frame: During the test session, takes about 3 minutes
Attention and psychomotor processing speed will be assessed with the Trail Making Test (TMT) from D-KEFS (Delis-Kaplan Executive Function System)
Time frame: During the test session, takes about 30 minutes
Episodic memory will be assessed with the Ray Auditory Verbal Learning Test (RAVLT).
Time frame: During the test session, takes about 5 minutes
Inhibition & task-set switching with the The Color-Word Interference Test (CWIT) from D-KEFS (Delis-Kaplan Executive Function System)
Time frame: Through study completion, an average of 1 year
Assessed with the Frändin-Grimby Scale (score 1-6, higher score=better)
Time frame: For one week after the test session
Assessed with accelerometers (Actigraph GT3X+)
Time frame: During the test session
Assessed with the movement Disorders Society- Unified Parkinson's Disease Rating Scale (MDS-UPDRS). Higher scores = worse/more symptoms
Time frame: During the test session
Assessed with the Mini-BESTest (Balance Evaluation Systems test), 0-28p,
Time frame: Will be answered before the test session in the patients home or during the test session
Assessed with Hospital Anxiety and Depression Scale (HADS), 0-24 on the depression and anxiety part respectively. Lower score=better
Time frame: Will be answered before the test session in the patients home or at the test session
Self assessed walking ability with the WALK-12G
Time frame: During the test session during dual task conditions
Cognitive performance of the dual task will be assessed as the reaction time to respond during Auditory stroop
Time frame: Will be answered before the test session in the patients home or during the test session
WHO Disability Assessment Schedule (WHODAS) version 2.0, 12 self-assessed questions (12 to 60) more points=worse
Karolinska Institutet
Other
Walking and Thinking - Brain Activity During Complex Walking in Aging and Parkinson's Disease (Part of the ParkMOVE Trial)
Acronym: ParkMOVE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05510739
Basal Ganglia Diseases, Behavior
Stockholm, Sweden
View Trial DetailsNCT03213873
Basal Ganglia Diseases, Behavior
Huddinge, Sweden
View Trial DetailsNCT05938673
Basal Ganglia Diseases, Brain Diseases
São Paulo, Brazil
View Trial DetailsNCT05110053
Basal Ganglia Diseases, Brain Diseases
Aarhus, Denmark
View Trial Details